Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (TLPPF)
OTHER OTC:TLPPF
TLPPF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.04 - $24.85
Previous CloseN/A
Volume500.00
Average Volume (3M)7.50K
Market Cap
$4.11B
Enterprise Value$8.56B
Total Cash (Recent Filing)$710.35M
Total Debt (Recent Filing)$581.45M
Price to Earnings (P/E)331.6
Beta1.41
Next Earnings
Feb 19, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding338,399,050
10 Day Avg. Volume9,746
30 Day Avg. Volume7,496
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.08
Enterprise Value/Revenue10.93
Enterprise Value/Gross Profit16.79
Enterprise Value/Ebitda92.46
Forecast
1Y Price Target
$19.77Price Target Upside79.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Market ExpansionIlluccix received a positive decision on the MAA in Europe and country approvals in Denmark, Ireland, Luxembourg, Malta, the Netherlands, Norway, and Sweden as well as MAA approval in the UK and Brazil.
Product ApprovalsApprovals of Zircaix and Pixclara and Illuccix reimbursement decisions ex-US could lead to increased revenue.
Revenue GrowthTelix reported Q1 total revenue of $186MM (AU$296MM, +31% Q/Q, +62% Y/Y), which could lead to an H1 beat as consensus currently estimates AU$547MM (vs the current H1 run-rate of AU$592).
Bears Say
Operating CostsHigher-than-expected operating costs relative to consensus expectations.
Pricing ImpactThe rule requires reimbursement based on MUC pricing as opposed to a typical discount to WAC, which could result in a slight impact to Q3 and Q4 sales.
Transitional Pass-through StatusThere is likely to be some impact on Illuccix revenue by the loss of transitional pass through status (TPT) on July 1.
Telix Pharmaceuticals News
TLPPF FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest stock price was $10.04 and its highest was $24.85 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is $4.11B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2026 which is in 176 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Aug 20, 2025. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.18 by -$0.17.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.15.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 338,399,050 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of $0.01 in its last earnings report, missing expectations of $0.18. Following the earnings report the stock price went up 9.589%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in TLPPF
Telix Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.77 (79.56% Upside)
$19.77 (79.56% Upside)
Blogger Sentiment
Bullish
TLPPF Sentiment 95%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.82%
12-Months-Change
Fundamentals
Return on Equity
3.21%
Trailing 12-Months
Asset Growth
138.86%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
TLPPF Company Deck
TLPPF Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in terms of revenue growth, product expansion, and strategic acquisitions, highlighting the company's robust cash position and pipeline advancements. However, challenges such as SEC inquiries, gross margin pressure, and competitive pricing pressures were noted.View all TLPPF earnings summariesTLPPF Stock 12 Month Forecast
Average Price Target
$19.77
▲(79.56% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Ownership Overview
6.64% Insiders
2.83% Mutual Funds
― Other Institutional Investors
86.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---